docetaxel anhydrous has been researched along with Carcinoma, Large Cell in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 23 (47.92) | 29.6817 |
| 2010's | 24 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Chang, J; Cheng, Y; Goto, K; Ichinose, Y; Lim, WT; Lu, S; Maemondo, M; Mok, TSK; Morita, S; Nakagawa, K; Nishio, M; Nokihara, H; Shi, YK; Soo, RA; Sugawara, S; Takahashi, T; Tamura, T; Yamamoto, N; Yang, JC; Zhang, L | 1 |
| Asai, Y; Gon, Y; Nakagawa, Y; Shimizu, T; Takahashi, N; Tsujino, I | 1 |
| Fleitas, T; Gómez-Codina, J; Martín, M; Martínez-Sales, V; Mesado, D; Montalar, J; Reganon, E; Reynés, G; Vila, V | 1 |
| Enoki, Y; Fujimoto, S; Fukui, A; Morishita, H; Okuyama, Y; Yoshida, N | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Fukuda, M; Gemma, A; Inoue, A; Isobe, H; Katakami, N; Kobayashi, K; Kubota, K; Kudoh, S; Kunitoh, H; Michimae, H; Minato, K; Nakamura, Y; Nishio, M; Ohmatsu, H; Okamoto, H; Sakai, H; Sugawara, S; Takeuchi, M; Takiguchi, Y; Yokoyama, A | 1 |
| Dermitzaki, EK; Georgoulias, V; Hatzidaki, D; Karavassilis, V; Katsaounis, P; Kentepozidis, N; Koinis, F; Kotsakis, A; Matikas, A; Mavroudis, D; Samantas, E; Varthalitis, II | 1 |
| Blanco, R; Camps, C; de Aguirre, I; Garrido, P; Gonzalez-Larriba, JL; Insa, A; Isla, D; Moran, T; Pérez Cano, M; Provencio, M; Queralt, C; Ramirez, JL; Rosell, R; Santarpia, M | 1 |
| Choy, H; Dobbs, T; Dowlati, A; Hughes, RS; Jain, AK; Muldowney, NJ; Sandler, AB; Schlabach, L; Schwartzberg, LS; Wu, J | 1 |
| López-González, A; Provencio, M; Sánchez, A; Yebra, M | 1 |
| Dalphin, JC; Depierre, A; Elleuch, R; Gainet, M; Girard, N; Jacoulet, P; Pernet, D; Westeel, V | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Cooper, J; Eaby, B; Evans, T; Kaiser, L; Kucharczuk, J; Langer, C; Rengan, R; Shrager, J; Stevenson, J; Weiss, J | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Ellerton, JA; Gettinger, SN; Hicks, W; Murren, JR; Otterson, GA; Pan, X; Villalona-Calero, MA | 1 |
| Belani, CP; Brodowicz, T; Fossella, F; Manegold, C; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K; Vansteenkiste, J; Zielinski, C | 1 |
| Barlesi, F; Berard, H; Chavaillon, JM; Chouabe, S; Descourt, R; Falchero, L; Fournel, P; Geriniere, L; Hureaux, J; Le Caer, H; Lena, H; Monnet, I; Robinet, G; Vergnenegre, A | 1 |
| Holmlund, JT; Karaseva, NA; Leopold, L; Luft, AV; Orlov, SV; Popovych, O; Ready, N; Wood, BA | 1 |
| Belzer, K; Burger, AM; Chen, W; Gadgeel, SM; Hackstock, D; Konski, A; Marquette, L; Patel, BB; Ruckdeschel, JC; Turrisi, A; Valdivieso, M; Wozniak, A | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Berrocal, A; Blasco, A; Blasco, S; Bremnes, RM; Caballero, C; Camps, C; Del Pozo, N; Iranzo, V; Jantus-Lewintre, E; Rosell, R; Sirera, R; Tarón, M | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Barraclough, H; Ganju, V; Kim, JH; Lee, DH; Magallanes, M; Martínez-Barrera, L; Orlando, M; Rodrigues-Pereira, J; van Kooten, M; Wang, J | 1 |
| Araki, T; Ishihara, H; Komiyama, T; Kuriyama, K; Nishikawa, K; Onishi, H; Tanaka, S; Yamaguchi, M | 1 |
| Senan, S | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Ishihara, S; Iwasaki, Y; Kaira, K; Minato, K; Mori, M; Saito, R; Sato, K; Takei, Y; Takise, A; Tsuchiya, S | 1 |
| Horai, T; Matsuda, M; Morikawa, A; Nakagawa, K; Nishio, M; Ohyanagi, F; Okumura, S; Sato, Y; Tabata, D | 1 |
| Chun, JH; Han, JY; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Yoon, SM | 1 |
| Adachi, Y; Bandobashi, K; Ikezoe, T; Kobayashi, M; Koeffler, HP; Nishioka, C; Taguchi, H; Takeuchi, S; Takeuchi, T; Yang, Y | 1 |
| Caterino, M; Cecere, FL; Ceribelli, A; Cognetti, F; Facciolo, F; Gelibter, AJ; Milella, M; Mirri, A; Pino, MS | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Mori, M; Saito, R; Sunaga, N; Tsuchiya, S; Watanabe, S; Yanagitani, N | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Nakao, S; Sone, T; Tambo, Y; Tamori, S | 1 |
| Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N | 1 |
| Earl, S; Gounaris, I; Lyons, B; Rahamim, J; Shivasankar, S; Yiannakis, D | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Ashcroft, L; Booton, R; Heighway, J; Morris, J; Thatcher, N; Ward, T | 1 |
| Albert, D; Bunn, PA; Kelly, K; Magree, L; Rusk, J; Vokes, EE; Weiss, GJ | 1 |
| Aguilo, R; Artal, A; Astudillo, J; Barcelo, JR; Cardenal, F; Domine, M; Garrido, P; González-Larriba, JL; Hernando-Trancho, F; Insa, A; Isla, D; Massuti, B; Muguruza, I; Provencio, M; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Tarrazona, V; Torres, A; Varela, A | 1 |
| Goto, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Androulakis, N; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kourousis, C; Maltezakis, G; Metaxaris, G; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Aoki, H; Fukai, S; Hashimoto, K; Hayashihara, K; Ishida, T; Kuwahara, K; Minegishi, Y; Nemoto, E; Okano, T; Saito, T; Watanabe, K; Watanabe, S; Yanai, N | 1 |
| Kato, Y; Nosaka, S; Tamura, K; Tumori, M; Yamane, Y; Yamauti, M | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Kato, Y; Kitagaki, H; Maruyama, R; Nishiki, M; Tumori, M; Uchida, N; Yamane, Y; Yamauti, M; Yoshida, M | 1 |
23 trial(s) available for docetaxel anhydrous and Carcinoma, Large Cell
| Article | Year |
|---|---|
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Young Adult | 2017 |
A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2019 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Quality of Life; Survival Rate; Taxoids; Tegafur | 2015 |
A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Dyspnea; Fatigue; Female; Gastrointestinal Diseases; Greece; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2016 |
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Double-Blind Method; Female; Follow-Up Studies; Gossypol; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Taxoids | 2011 |
Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Survival Rate; Taxoids; Thymidylate Synthase; Treatment Outcome | 2011 |
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Taxoids | 2011 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2005 |
A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2007 |
A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Taxoids; Treatment Outcome | 2007 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; DNA Repair; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mitomycin; Neoplasm Staging; Neoplasms, Squamous Cell; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Sulindac; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2007 |
First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Recombinant Proteins; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
25 other study(ies) available for docetaxel anhydrous and Carcinoma, Large Cell
| Article | Year |
|---|---|
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Taxoids; Vascular Endothelial Growth Factor A | 2013 |
A large cell neuroendocrine carcinoma of the gall bladder: diagnosis with 18FDG-PET/CT-guided biliary cytology and treatment with combined chemotherapy achieved a long-term stable condition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Disseminated Intravascular Coagulation; Docetaxel; Fatal Outcome; Fluorodeoxyglucose F18; Gallbladder Neoplasms; Humans; Immunohistochemistry; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Treatment Failure | 2013 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Immunoenzyme Techniques; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2017 |
False-positive interpretations in respiratory cytopathology.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Diagnostic Errors; Docetaxel; False Positive Reactions; Granulomatosis with Polyangiitis; Humans; Irinotecan; Lung Neoplasms; Male; Radiography, Thoracic; Remission Induction; Taxoids; Treatment Outcome | 2013 |
Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA Repair; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Polymorphism, Genetic; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2003 |
Reply to "Radiation pneumonitis and docetaxel".
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2004 |
Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Antipyrine; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytochrome P-450 Enzyme System; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Survival Rate; Taxoids; Treatment Outcome | 2005 |
NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Down-Regulation; Drug Combinations; Glycogen Synthase Kinases; HIV Protease Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nelfinavir; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Taxoids; Tumor Suppressor Protein p53 | 2006 |
[A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Remission Induction; Taxoids; Tegafur; Vinblastine; Vinorelbine | 2007 |
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Dacarbazine; Docetaxel; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Quality of Life; Taxoids; Temozolomide | 2007 |
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2008 |
[Effectiveness of docetaxel plus cisplatin in large cell lung cancer showing little response to prior chemotherapy with MVP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Taxoids; Treatment Failure; Vindesine | 2000 |
[A case of adrenal metastasis of lung cancer treated by carboplatin and docetaxel].
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Male; Paclitaxel; Taxoids | 2001 |
[A case of large-cell lung cancer successfully treated with docetaxel in combination with carboplatin and radiotherapy].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids | 2002 |